Background/Objectives: Non-ablative local therapies are increasingly used in the conservative management of human papillomavirus (HPV) infection. Coriolus versi-color, an immunomodulatory medicinal mushroom, is one such approach. This study aimed to investigate the effect of a Coriolus versicolor–based vaginal gel on HPV clearance and cervical cytological outcomes. Methods: This retrospective cohort study included 600 women with cervical HPV infection (300 treated with a Coriolus versi-color–based vaginal gel and 300 receiving standard follow-up). Baseline and six-month follow-up assessments included HPV DNA testing and cervical cytology. Results: Baseline demographic characteristics, HPV genotype distribution, and cytological findings were comparable between the groups. Overall HPV clearance was signifi-cantly higher in the treatment group than in the control group (89.3% vs. 44.7%, p < 0.001). Complete clearance of high-risk HPV genotypes, including HPV 16 (77.0% vs. 25.4%, p < 0.001) and HPV 18 (73.9% vs. 18.5%, p = 0.017), was also significantly more frequent among treated women. Cytological normalization occurred more often in the treatment group (88.4% vs. 60.4%, p < 0.001). Multivariable analysis identified use of the vaginal gel as the strongest independent factor associated with HPV clearance (adjusted odds ratio [aOR] = 8.45; 95% confidence interval [CI]: 3.05–23.43; p < 0.001). Conclusions: Treatment with a Coriolus versicolor–based vaginal gel was associated with significantly higher rates of high-risk HPV clearance and cervical cytological normalization. These findings suggest that this therapy may represent an effective ad-junct in the conservative management of HPV infection; however, randomized con-trolled trials are warranted to confirm these results.

Objective:To evaluate the effects of Papivir/Pavirona® tablets, containing cinnamon extract, selenium, quercetin, licorice root, and green tea extract, on cervical human papillomavirus (HPV) clearance and cytological outcomes in women with cervical HPV infection. Methods: This retrospective cohort study included 239 women with con-firmed cervical HPV infection, followed at a tertiary referral center between February 2023 and August 2025. Participants were classified into a treatment group receiving oral Papivir/Pavirona® twice daily for six months (n = 119) and a control group managed with routine clinical follow-up alone (n = 120). HPV DNA testing and cervical cytology were evaluated at baseline and during follow-up visits at 6 and 12 months. Results: HPV clearance rates were significantly higher among Papivir/Pavirona® users at both 6 and 12 months compared with controls (67.2% vs. 29.2% and 69.1% vs. 46%, respectively). Cytological regression was also more frequent in the Papivir/Pavirona® group at 6 months (81.1% vs. 54.5 %) and 12 months (77.9% vs. 52.8%). In multivariate logistic re-gression analysis, Papivir/Pavirona® use emerged as an independent predictor of both HPV clearance and cytological regression, whereas demographic, reproductive, behav-ioral, and virological baseline characteristics were not significantly associated with outcomes. Conclusions: It has been suggested that Papivir/Pavirona® supplementation is associated with increased HPV clearance and cytological regression rates in women with cervical HPV infection, and may play a potential supportive role in cervical HPV management.